Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Regulatory News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

Share Price is delayed by 15 minutes
Get Live Data
8.25    1.10 (14.86%)
Bid:
8.00
Ask:
8.50
Spread: 0.50 (6.25%)
Market Cap: £59.93m
POLB Live PriceLast checked at - London Stock Exchange

Intraday Poolbeg Pharma Share Chart

Form 8.3 - Poolbeg Pharma plc

18 Feb 2025 17:04

RNS Number : 5805X
Poolbeg Pharma PLC
18 February 2025
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Michael Kelly

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Poolbeg Pharma plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

N/A

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

10 January 2025

 

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary Shares of 0.02p

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

 

35,443,132

 

7.09%

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

 

35,443,132

 

7.09%

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary Shares of 0.02p

Purchase

728,191

 

0.4836

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

None

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

18 February 2025

Contact name:

Michael Kelly

Telephone number*:

N/A

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETGZGMZNRFGKZM
Date   Source Headline
9th Jan 20254:28 pmRNSForm 8.5- Poolbeg Pharma PLC
9th Jan 202511:01 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
9th Jan 20258:53 amRNSForm 8.5 (EPT/NON-RI)
9th Jan 20257:00 amRNSHolding(s) in Company
8th Jan 20253:56 pmRNSForm 8.5 (EPT/NON-RI) - Poolbeg Pharma PLC
8th Jan 20253:53 pmRNSForm 8 (OPD) - Poolbeg Pharma plc
8th Jan 202510:51 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
8th Jan 20259:44 amRNSForm 8.5 (EPT/NON-RI)
7th Jan 202510:54 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
7th Jan 202510:48 amRNSForm 8.5 (EPT/NON-RI)
7th Jan 20257:00 amRNSUpdate Potential Combination of Poolbeg & HOOKIPA
6th Jan 202510:27 amRNSForm 8.5 (EPT/NON-RI)
6th Jan 202510:19 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
3rd Jan 202511:40 amRNSForm 8.5 (EPT/NON-RI)
3rd Jan 202511:34 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
2nd Jan 20257:00 amRNSCombination of Poolbeg and HOOKIPA Pharma Inc.
20th Nov 20247:00 amRNSPOLB 001 Patent Granted in United States
18th Sep 20247:00 amRNSInterim results for the six months to 30 June 2024
12th Aug 20241:28 pmRNSHolding(s) in Company
26th Jul 20247:00 amRNSVoluntary Delisting from OTCQB Market
10th Jul 20247:00 amRNSNotification of Major Holdings
2nd Jul 20247:00 amRNSChange of Registered Address
17th Jun 20248:38 amRNSResult of AGM
9th May 20247:00 amRNSAnnual Report & AGM Notice
1st May 20247:00 amRNSSignificant POLB 001 Patent Granted in USA
30th Apr 20247:02 amRNSAppointment of Joint Broker
30th Apr 20247:01 amRNSOption Agreement to Acquire Orphan Drug Candidate
30th Apr 20247:00 amRNSResults for the year ended 31 December 2023
29th Apr 20247:00 amRNSTR-1: Notification of major holdings
22nd Feb 20247:00 amRNSDirector/PDMR Shareholding
19th Feb 20241:42 pmRNSDirector Share Purchase
15th Feb 20247:00 amRNSBoard Role Change and Launch of EIP
17th Jan 20247:00 amRNSFurther data shows POLB001 potential in cancer CRS
20th Dec 20237:00 amRNSRSV AI Drug Candidate Analysis Update
11th Dec 20237:00 amRNSPOLB 001 Data Presented at ASH
30th Nov 20237:00 amRNSDirectorate Change
21st Nov 20237:00 amRNSImmunomodulator II patent granted in Japan
16th Nov 20237:00 amRNSPOLB 001 LPS Trial Data to be Presented at IUIS
9th Nov 20237:00 amRNSFormer Amryt Pharma Leadership Team join Poolbeg
3rd Nov 20237:05 amRNSPOLB001 Data to be Presented at ASH Annual Meeting
1st Nov 20237:00 amRNSPOLB 001 Oncology Programme Update Meeting
26th Oct 20237:00 amRNSSAB Endorses Influenza Drug Targets
17th Oct 20237:00 amRNSPoolbeg Partners with a Nasdaq-Listed Biopharma
29th Sep 20237:00 amRNSFavourable Conclusion of Patent Opposition
20th Sep 20237:00 amRNSImmunomodulator I Patent Portfolio Strengthened
19th Sep 20237:00 amRNSImmunomodulator I Patent Opposition Withdrawal
13th Sep 20237:00 amRNSInterim results for the six months to 30 June 2023
29th Jun 20237:00 amRNSAI led programme identifies influenza drug targets
22nd Jun 20237:00 amRNSOral Vaccine Programme Moves Forward
24th May 20237:00 amRNSBoard Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.